I-Mab Stock Price, News & Analysis

I-Mab (NASDAQ: IMAB) announced a poster presentation at the 2021 AACR Annual Meeting showcasing uliledlimab (TJD5), a novel CD73 blocking antibody. This innovative treatment targets adenosine-rich cancer microenvironments with unique binding properties, providing potential anti-tumor activity in combination with PD-(L)1 therapies. Additionally, an abstract has been submitted for the phase 1 study of uliledlimab and atezolizumab, indicating ongoing clinical evaluation. The meeting will occur virtually from April 10-15, 2021.

I-Mab (Nasdaq: IMAB) has announced new collaborations with Complix and Affinity to enhance its drug discovery capabilities in immuno-oncology. These partnerships will provide access to advanced technology platforms including Cell Penetrating Alphabodies and tumor-site activated masked antibodies, aimed at developing innovative cancer therapeutics. The company remains focused on advancing its existing clinical programs while expanding its pipeline of novel drug candidates. I-Mab's strategy underscores its commitment to scientific leadership and innovation in the biopharmaceutical sector.

I-Mab (Nasdaq: IMAB), a biopharmaceutical firm, will announce its financial results for the full year ending December 31, 2020, before the market opens on March 29, 2021. A conference call is scheduled for 8:00 a.m. ET on the same day, where the company will provide a corporate update. I-Mab aims to advance from a clinical stage to a fully integrated company with a robust pipeline of over 15 drug candidates in the immuno-oncology field. The call requires prior registration, and a replay will be available on the company’s website.

I-Mab (Nasdaq: IMAB) has announced the dosing of the first patient in the pivotal phase 3 trial for eftansomatropin alfa, targeting pediatric growth hormone deficiency in China. This long-acting recombinant human growth hormone is designed to improve patient compliance by allowing weekly injections, in contrast to daily alternatives. The trial will enroll 165 patients, comparing eftansomatropin alfa with Norditropin over 52 weeks. A successful trial could significantly improve the quality of life for children with growth hormone deficiency, addressing a substantial unmet need in China.

I-Mab (Nasdaq: IMAB) announced its participation in several upcoming virtual conferences in March 2021. Key conferences include the H.C. Wainwright Global Life Sciences Conference on March 9, the Credit Suisse Asian Investment Conference from March 22-26, and the Morgan Stanley Hong Kong Summit from March 29-31. Notable management participants include Dr. Jingwu Zang, Dr. Joan Huaqiong Shen, and CFO Jielun Zhu. The company is committed to advancing its pipeline of biologics in the immuno-oncology sector, aiming for rapid commercialization and global presence.

I-Mab (Nasdaq: IMAB) announced the clearance of its IND application by China's NMPA for TJ210/MOR210, allowing the initiation of a phase 1 clinical trial. This trial aims to evaluate the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors. TJ210/MOR210, a monoclonal antibody targeting C5aR1, is designed to block tumor-promoting immune cells. The trial follows similar studies in the U.S. and is expected to accelerate drug development for patients who have not responded to existing therapies.

I-Mab (Nasdaq: IMAB) announced a follow-on public offering of 3,283,950 American depositary shares, priced at US$54.00 each, by certain pre-IPO shareholders. The offering includes a 30-day option for underwriters to buy an additional 492,590 ADSs. Proceeds will not benefit the company as they are being sold by existing shareholders. The offering is made via a prospectus supplement filed with the SEC on February 5, 2021. The company focuses on developing novel biologics in the immuno-oncology field, with a pipeline of over 15 drug candidates.

I-Mab (Nasdaq: IMAB) announced a proposed registered underwritten public offering by certain pre-IPO shareholders of 3,283,950 American depositary shares (ADSs), each representing 23 ordinary shares. An additional option allows underwriters to purchase 492,590 more ADSs. The company will not receive proceeds from this sale. The offering is made under an automatic shelf registration statement filed with the SEC on February 5, 2021. BofA Securities, Piper Sandler, and Cantor Fitzgerald are joint bookrunners for the offering.

I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, has announced significant clinical advancements for its CD73 antibody, uliledlimab (TJD5), targeting advanced solid tumors. The company has initiated a phase 1/2 study in China and completed initial assessments in the U.S., demonstrating the safety and clinical activity of uliledlimab in combination with PD-1 inhibitors. Detailed results are expected at major conferences in 2021. I-Mab aims to offer innovative therapies for patients unresponsive to existing treatments.